Daré Bioscience Announces End-of-Phase 2 Meeting With FDA On Development Of Sildenafil Cream, 3.6%; Co. And FDA Aligned On Key Elements Of Phase 3 Program
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience has completed an end-of-Phase 2 meeting with the FDA regarding the development of its Sildenafil Cream, 3.6%. The company reports alignment with the FDA on the key elements of the Phase 3 program, which is a positive step towards advancing the product's development.
January 31, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daré Bioscience has successfully aligned with the FDA on the Phase 3 development of its Sildenafil Cream, 3.6%, which is likely to be viewed positively by investors.
The successful end-of-Phase 2 meeting with the FDA and alignment on the Phase 3 program are significant milestones for Daré Bioscience. This news indicates progress in the drug's development pathway and can lead to increased investor confidence in the company's ability to bring the product to market. As a result, there may be a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100